首页> 外文期刊>National Journal of Community Medicine >A Study on Compliance to Allergen Immunotherapy in Respiratory Allergy
【24h】

A Study on Compliance to Allergen Immunotherapy in Respiratory Allergy

机译:呼吸道过敏对过敏原免疫治疗依从性的研究

获取原文
       

摘要

"Introduction: Respiratory allergic diseases requires administration of Allergen immunotherapy at frequent intervals for a period of time which is usually 3-5 years which makes compliance issues particularly relevant. Objectives: To describe socio-demographic profile of study sub-jects and to assess various factors influencing compliance to allergen immunotherapy. Methods: A prospective longitudinal study conducted at Allergy clinic, Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore. Data was collected by review of the individual records of all the patients who were started on allergen immunotherapy during January 2011 – December 2014 (3 years). Reason for discontinuation of treatment was collected through phone calls. Results: There were 109 (53.96%) males and 93 (46.04%) females. Majority i.e. 146 (72.27%) were in the age group of 21- 40 years. There were 117 (57.92%) on allergen Immunotherapy for House dust mite only, 42 (20.79%) for pollen only and 43 (21.29%) for both house dust mite and pollen. 15 (7.43%) subjects have completed 3 years treatment, 125 (60.40%) are continuing treatment and 63 (30.69%) have discontinued treatment (Non-compliance). Commonest reasons for non-compliance were no improvement, afar hospital and adverse reactions. Conclusion: Non-compliance to allergen immunotherapy was 30.69% and commonest reason for non-compliance was no im-provement.
机译:“引言:呼吸道过敏性疾病要求经常间隔进行过敏原免疫疗法,通常为3-5年,这使得依从性问题尤为重要。目标:描述研究对象的社会人口统计学特征并评估各种方法:在班加罗尔Kempegowda医学科学研究所社区医学系变态反应诊所进行的前瞻性纵向研究,通过回顾所有开始进行变应原免疫治疗的患者的个人记录收集数据在2011年1月至2014年12月(3年)期间,通过电话收集了终止治疗的原因结果:男性109例(53.96%),女性93例(46.04%),其中多数为146例(72.27%)。年龄在21至40岁之间的人群,仅针对屋尘螨的过敏原免疫疗法为117(57.92%),仅针对花粉为42(20.79%)。室内尘螨和花粉的含量均为43(21.29%)。 15名(7.43%)受试者已完成3年治疗,125名(60.40%)正在继续治疗,而63名(30.69%)已终止治疗(未达标)。违规的最常见原因是没有改善,远距离住院和不良反应。结论:过敏原免疫治疗的不合规率为30.69%,不合规的最常见原因没有改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号